Drugs / vunakizumab
Trials 18
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT06881290 | May 2025 → Nov 2026 expected | systemic lupus erythematosus | Chinese SLE Treatment And Research Group | Recruiting | No outcome recorded |
| Phase 1 | NCT06182384 | Dec 2023 → May 2024 | psoriasis | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04326881 | Apr → Jul 2020 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03710681 | Aug 2018 → Apr 2019 | psoriasis | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03704428 | Apr 2018 → Jan 2020 | spondyloarthropathy | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02934412 | Aug 2016 → Jun 2017 | psoriasis | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT03463187 | Dec 2017 → Aug 2020 | psoriasis | Jiangsu HengRui Medicine Co., Ltd. | Completed | Met primary |
| Phase 25 trials · 1 met primary | ||||||
| Phase 2 | NCT07069270 | Sep 2025 → Jun 2026 overdue | small cell lung carcinoma | Fujian Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05394857 | Sep 2022 → Aug 2023 | disease of orbital part of eye adnexa | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT05055934 | Oct 2021 → Jun 2024 | psoriatic arthritis | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Completed | Met primary |
| Phase 2 | NCT04924296 | Jun → Dec 2021 | lupus nephritis | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04121143 | Nov 2019 → Jun 2020 | psoriasis | Jiangsu HengRui Medicine Co., Ltd. | Suspended | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT04840485 | Jun 2021 → Nov 2023 | ankylosing spondylitis | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Completed | Met primary |
| Phase 34 trials · 1 met primary | ||||||
| Phase 3 | NCT06860750 | Apr 2025 → Feb 2028 expected | spondyloarthropathy | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06833307 | Feb 2025 → Jul 2026 overdue | — | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06640257 | Nov 2024 → Apr 2026 overdue | psoriatic arthritis | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT04839016 | Apr 2021 → Aug 2023 | psoriasis | Jiangsu HengRui Medicine Co., Ltd. | Unknown | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT06779097 | Feb 2025 → Mar 2027 expected | psoriasis | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT07373847 Background | Jan 2026 → Jun 2027 expected | psoriasis | Xiangya Hospital of Central South University | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-05-27 | Jiangsu HengRui Medicine Co., Ltd. | Results 恒瑞医药夫那奇珠单抗治疗活动性强直性脊柱炎Ⅱ/Ⅲ期研究结果发表于JAMA Network Open hengrui.com ↗
第16周，夫那奇珠单抗组ASAS 20应答率65.6%，显著高于安慰剂组的42.5%，组间差异23.2%（95% CI：11.8%-34.0%，P<0.001），ASAS 40应答率也明显高于安慰剂组（46.3% vs. 24.0%，P<0.0001）。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-05-27 | Jiangsu HengRui Medicine Co., Ltd. | 恒瑞医药夫那奇珠单抗治疗活动性强直性脊柱炎Ⅱ/Ⅲ期研究结果发表于JAMA Network Open hengrui.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vunakizumab | “Vunakizumab (SHR-1314) is a novel IL-17A monoclonal antibody that has demonstrated great efficacy and safety in treating moderate-to-severe plaque psoriasis.” PMID 40947125 ↗ Sep 20256“Vunakizumab (SHR-1314) is a novel interleukin 17A monoclonal antibody that has shown preliminary efficacy and tolerability in phase I trials.” PMID 35026342 ↗ Jan 2022 “Vunakizumab (SHR-1314) is a novel humanized mAb targeting IL-17A.” PMID 41632483 ↗ Feb 2026 |
| Known as | SHR-1314 | “Vunakizumab (SHR-1314) is a novel interleukin 17A monoclonal antibody that has shown preliminary efficacy and tolerability in phase I trials.” PMID 35026342 ↗ Jan 202214“Vunakizumab (SHR-1314) is a novel humanized mAb targeting IL-17A.” PMID 41632483 ↗ Feb 2026 “SHR-1314 subcutaneous injection” NCT04121143 ↗ |
| Action | Inhibit | “a novel anti-interleukin (IL) 17A monoclonal antibody” PMID 42101839 ↗ May 2026 |
| Modality | Monoclonal antibody | “Vunakizumab (SHR-1314) is a novel interleukin 17A monoclonal antibody that has shown preliminary efficacy and tolerability in phase I trials.” PMID 35026342 ↗ Jan 2022 |
| Route | Subcutaneous | “administered subcutaneously to healthy subjects” NCT02934412 ↗ |
| Target | IL17A | “anti-interleukin-17A antibody” PMID 39332633 ↗ Sep 2024 |